Trial · NCT03018834
Registered outcomes15
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of days alive free of any myocarditis complications | within 28 days post hospitalization | Number of days alive free of any myocarditis complications defined as ventricular arrhythmias, heart failure, chest pain, ventricular dysfunction defined as LVEF\<50%, within 28 days post hospitalization |
| Secondary | Total cost | on average 14 days | Total cost |
| Secondary | Total Quality Adjusted Life Year (QALYs), | on average 14 days | measure of the perceived utility by patients of a medication (Anakinra) that corresponds to a year of life gained |
| Secondary | Incremental cost effectiveness | on average 14 days | cost-effectiveness of ANAKINRA in the setting of acute myocarditis |
| Secondary | Cost utility ratios | on average 14 days | Cost utility ratios |
| Secondary | Left Ventricul Ejection Fraction (LVEF) assessed by cardiac Magnetic Resonance Imaging (MRI) | at 6 month | Left Ventricul Ejection Fraction (LVEF) assessed by cardiac Magnetic Resonance Imaging (MRI) |
| Secondary | Left Ventricul Ejection Fraction (LVEF) assessed by Trans Thoracic Echocardiograhy (TTE) | at 6 month | Left Ventricul Ejection Fraction (LVEF) assessed by Trans Thoracic Echocardiograhy (TTE) |
| Secondary | LVEF assessed by cardiac MRI | at 1 year | LVEF assessed by cardiac MRI |
| Secondary | LVEF assessed by cardiac TTE | at 1 year | LVEF assessed by cardiac TTE |
| Secondary | All cause of death rate | during the 12 months follow-up | All cause of death rate |
| Secondary | Cardiovascular death | at 12 months | Cardiovascular death |
| Secondary | Heart Failure | at 12 months | Heart Failure |
| Secondary | Ventricular tachycardia | during the 12 months follow-up | Ventricular tachycardia |
| Secondary | NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) or BNP ≤ 400pg/mL 50% decrease of the troponin level at discharge compared to admission | at Day0 | NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) or BNP ≤ 400pg/mL 50% decrease of the troponin level at discharge compared to admission |
| Secondary | NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) or BNP ≤ 400pg/mL 50% decrease of the troponin level at discharge compared to admission | an average of 14 days | NT-proBNP above 450 pg/mL (in patients aged below 50); above 900 pg/mL (age 50-75 years) or BNP ≤ 400pg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03018834/registered